NGSMM - Overview: NGSMM Next-Generation Sequencing (NGS), Multiple Myeloma

Test Catalog

Test Name

Test ID: NGSMM    
NGSMM Next-Generation Sequencing (NGS), Multiple Myeloma

Useful For Suggests clinical disorders or settings where the test may be helpful

Evaluation of multiple myeloma at the time of diagnosis, for prognostic, and potential therapeutic indications

 

Determine the presence of new clinically important gene mutation changes at relapse

Genetics Test Information Provides information that may help with selection of the correct test or proper submission of the test request

This test includes next-generation sequencing to evaluate for the following 61 genes and intronic regions: AKT1, AKT2, AKT3, AKT3-G, ATM, B2M, BIRC2, BIRC3, BRAF, CCND1, CD38, CDK4, CDK7, CDKN1B, CDKN2A, CDKN2A-G, CRBN, CUL4A, CUL4B, CXCR4, DIS3, DIS3-G, EGFR, FAM46C, FGFR3, FGFR3-G, GRB2, IDH1, IDH2, IDH3A, IFNGR2, IGF1R, IKZF1, IKZF3, IL6, IL6R, IRF4, JAK2, KDM6A, KDM6A-G, KRAS, MYC, MYD88, NFKB2, NR3C1, NRAS, NSD2, PIK3CA, PIK3CG, PIK3R1, PIK3R1-G, PIK3R2, PIM1, PIM2, PIM3, PSMA1, PSMB5, PSMB5-G, PSMD1, PSMG2, PTPN11, RB1, STAT3, TGFBR2, TLR4, TP53, TRAF3, AND XBP1.

Highlights

Next-generation sequencing detection of somatic gene mutations in multiple myeloma may have prognostic, and potential therapeutic implications.

 

This test is appropriate for diagnosis and disease relapse.

Additional Tests Lists test(s) that are always performed, at an additional charge, with the initial test(s)

Test IDReporting NameAvailable SeparatelyAlways Performed
CKNMMNGSMM Pre-Analysis Cell Sorting, BMNo, (Bill Only)Yes

Testing Algorithm Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.

See Targeted Genes Interrogated by Multiple Myeloma Next-Generation Sequencing in Special Instructions for a list of the genes and exons targeted by this assay.

Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test

Method Name A short description of the method used to perform the test

Somatic Mutation Detection by Next-Generation Sequencing (NGS)

NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.

Conditional

Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name

NGS Multiple Myeloma

Aliases Lists additional common names for a test, as an aid in searching

AKT1
AKT2
AKT3
ATM
B2M
BIRC2
BIRC3
BRAF
CCND1
CD38
CDK4
CDK7
CDKN1B
CDKN2A
CRBN
CUL4A
CUL4B
CXCR4
DIS3
EGFR
FAM46C
FGFR3
GRB2
IDH1
IDH2
IDH3A
IFNGR2
IGF1R
IKZF1
IL6
JAK2
KDM6A
KRAS
MYC
MYD88
NFKB2
NR3C1
NRAS
PIK3CA
PIK3CG
PIK3R1
PIK3R2
PIM1
PIM2
PIM3
PSMA1
PSMB5
PSMD1
PSMG2
PTPN11
RB1
STAT3
TGFBR2
TLR4
TP53
TRAF3
XBP1
Next gen sequencing of myeloma
Next gen sequencing of plasma cell myeloma
Next Gen Sequencing Test
NGS cancer panel, multiple myeloma
Somatic mutation detection by next generation sequencing (NGS), myeloma
IL6R
IRF4
Multiple myeloma
IKZF3